Prima BioMed Initiates Phase-2b Breast Cancer Trial
Edison | Jan 04, 2016 12:08PM ET
Prima Biomed Ltd. (O:PBMD) has initiated a Phase IIb study of IMP321 in metastatic breast cancer, marking the start of a period of expected strong newsflow from its in-house and partnered LAG-3 programmes in cancer and autoimmune diseases. The trial represents the return to the clinic of IMP321, a soluble LAG-3 fusion protein that doubled the tumour response rate vs chemo alone in Phase IIa, which was acquired with the other LAG-3 programmes with the purchase of Immutep in late 2014. The proceeds of the recent capital raise increase our valuation to A$273m (vs A$271m).
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.